Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05067387
Other study ID # 21-007289
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date April 2024
Est. completion date March 2026

Study information

Verified date November 2023
Source University of California, Los Angeles
Contact Ziva Cooper, PhD
Phone 310-206-9942
Email zcooper@mednet.ucla.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.


Description:

This double-blind placebo controlled, within-subject study study will assess testing devices that can measure biochemical markers in oral fluid and neurocognitive-performance markers of recent THC or CBD use. Other pharmacodynamic effects of oral THC or CBD will be determined and the pharmacokinetics of THC, CBD, and respective metabolites will be assessed in whole blood.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 22
Est. completion date March 2026
Est. primary completion date March 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 55 Years
Eligibility Inclusion Criteria: - Male or non-pregnant and non-lactating females aged 21-55 years - Report weekly-monthly use of cannabis (=1 day per week) over the past month prior to screening, - Not currently seeking treatment for their cannabis use - Have a Body Mass Index from 18.5 - 34kg/m2. - Able to perform all study procedures - Must be using a contraceptive (hormonal or barrier methods) Exclusion Criteria: - Meeting DSM-V criteria for moderate to severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine - Any other Axis I disorder - Report using other illicit drugs in the prior 4 weeks, other than cannabis. - Current use of any medications that may affect study outcomes - If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process are not within the normal range and / or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures. - Pregnancy is exclusionary due to the possible effects of the study medication on fetal development. - History of an allergic reaction or adverse reaction to cannabis is exclusionary. - History of respiratory illness or current respiratory illness - Currently enrolled in another research protocol - Not using a contraceptive method (hormonal or barrier methods) - The evaluating physician reviews all medical assessments along with medical history. Any disorders that might make cannabis administration hazardous are exclusionary.

Study Design


Intervention

Drug:
Placebo
Oral placebo
THC
Oral THC (20 mg)
CBD
Oral CBD (20 mg)
THC + CBD
Oral THC (20 mg) + CBD (20 mg)

Locations

Country Name City State
United States University of California, Los Angeles Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Ratings of subjective drug effects Average and peak subjective ratings of drug effects associated with abuse liability as measured using visual analogue scales (VAS; 1-100mm). 6 hours
Primary Concentration of THC, CBD and metabolites in whole blood Peak blood levels of THC, CBD, 11-OH-THC, and THCCOOH as measured in ng/ml 6 hours
Primary Behavioral task performance as assessed by the DRUID App Score Composite score on the DRUID App, a measure of behavioral task performance (range 0-100) where lower scores indicate better performance 6 hours
Primary Concentration of THC in oral fluid Liquid chromatography-tandem mass spectrometry 6 hours
See also
  Status Clinical Trial Phase
Completed NCT02224508 - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks N/A
Completed NCT02282306 - Phone Interview to Prevent Recurring Opioid Overdoses N/A
Completed NCT02375516 - Preventing Drug Abuse Among Hispanic Adolescents N/A
Completed NCT01442753 - Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth N/A
Withdrawn NCT01275391 - cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use Phase 1/Phase 2
Completed NCT00907309 - Dental and Medical Office iMET to Reduce Teen Tobacco, Alcohol, and Drug Use Phase 1/Phase 2
Completed NCT02228044 - Alcohol, Suicide and HIV Prevention for Teens in Mental Health Treatment N/A
Withdrawn NCT01427465 - Brief Integrative Alcohol Interventions for Adolescents N/A
Completed NCT00350909 - Brief Intervention for Drug Abusing Adolescents Phase 2
Completed NCT00148031 - Improving Hepatitis C Treatment in Injection Drug Users Phase 4
Completed NCT00383838 - Self-Selected Brief Alcohol Intervention for Adolescents N/A
Completed NCT00722644 - Cognitive Behavioral Stress Management for HIV+ Drug Abusers Phase 1
Completed NCT00451854 - Student Athlete Testing Using Random Notification N/A
Completed NCT01036711 - Effects of Nicotine on Cognitive Task Performance and Brain Activity as Measured by fMRI
Terminated NCT02741076 - Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain Phase 4
Completed NCT01035723 - Effect of Functional Genetic Polymorphisms on Brain Morphology and Function
Completed NCT06044363 - Satir Model for Self-esteem, Mental Health, and Family Function Among Individuals With Substance Use Disorders N/A
Recruiting NCT05037487 - Evaluation of Smoked THC and CBD in Men and Women Phase 1
Recruiting NCT04725266 - A Family-based Intervention for Drug-abusing Adults in Hong Kong N/A
Completed NCT03678051 - CBT4CBT for Women in Residential Treatment for Substance Use Disorders N/A